Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Encorafenib (BRAFTOVI™) to Treat Patients with BRAFV600E-Mutant Metastatic Colorectal Cancer (mCRC)

Encorafenib (BRAFTOVI™), in combination with binimetinib (MEKTOVI®) and cetuximab has been designed to treat patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC).

BRAFV600E-mutant mCRC will be an important treatment option to the cancer patients in critical need.

The results were made from the safety lead-in of the ongoing randomised Phase 3 BEACON CRC trial showed that, at the time of analysis, the Overall Survival (OS) data were fully mature through 12.6 months and that the median OS had not yet been reached.

The one-year overall survival rate for this cohort was 62 per cent.

Median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95 per cent CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines of therapy.

Confirmed Overall Response Rate (ORR) was 48 per cent and among the 17 patients who received only one prior line of therapy the ORR was 62 per cent.

The triplet combination was generally well-tolerated with no unexpected toxicities.

The most common grade 3 or 4 adverse events seen in at least 10 per cent of patients were fatigue (13%), anemia (10%), increased blood creatine kinase (10%) and increased aspartate aminotransferase (10%).

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024